Collectively, these data indicate that breast cells harbouring oncogenic PIK3CA mutations have enhanced dependence on RNMT (mRNA cap methylation) for proliferation and survival, making RNMT a promising therapeutic target in PIK3CA mutant breast cancer. The gene discussed is PIK3CA; the disease is breast cancer.